Skip to main content

Eli Lilly and Company Zepbound revenue

  • LLY · NYSE
  • Pharmaceuticals
  • S&P 500
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.36T

Zepbound revenue at Eli Lilly and Company came to $5.3B for the quarter to 30 Sep 2026, up 47.6% from a year earlier.

As Eli Lilly and Company reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 29 Oct 2026.

By quarter

$175.8MDec 2023$517.4MMar 2024$1.2BJun 2024$1.3BSep 2024$1.9BDec 2024$2.3BMar 2025$3.4BJun 2025$3.6BSep 2025$4.2BDec 2025$4.1BMar 2026$4.9BJun 2026$5.3BSep 2026
Eli Lilly and Company Zepbound revenue, every reported period
Period endingZepbound revenueChange on a yearFiled
30 Sep 2026$5.3Bup 47.6%29 Oct 2026
30 Jun 2026$4.9Bup 44.2%5 Aug 2026
31 Mar 2026$4.1Bup 79.3%30 Apr 2026
31 Dec 2025$4.2Bup 121.8%12 Feb 2026
30 Sep 2025$3.6Bup 183.7%30 Oct 2025
30 Jun 2025$3.4Bup 171.9%7 Aug 2025
31 Mar 2025$2.3Bup 345.5%1 May 2025
31 Dec 2024$1.9Bup 984.9%19 Feb 2025
30 Sep 2024$1.3B—30 Oct 2024
30 Jun 2024$1.2B—8 Aug 2024
31 Mar 2024$517.4M—30 Apr 2024
31 Dec 2023$175.8M—21 Feb 2024
30 Sep 2023$0—2 Nov 2023
30 Jun 2023$0—8 Aug 2023
31 Mar 2023$0—27 Apr 2023

Definition

Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Eli Lilly and Company: Cardiometabolic Health revenue · Mounjaro revenue · Oncology revenue · Verzenio revenue · Immunology revenue · Jardiance revenue · Trulicity revenue · Taltz revenue · Neuroscience revenue · United States revenue · Outside U.S. revenue · Europe revenue · Rest of world revenue · China revenue · Japan revenue · financial statements

Every KPI and segment of LLY, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.